TheStreet cut shares of Opiant Pharmaceuticals (NASDAQ:OPNT) from a c+ rating to a d+ rating in a report published on Monday morning.

Separately, ValuEngine lowered Opiant Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, October 2nd.

Opiant Pharmaceuticals (NASDAQ OPNT) opened at $23.50 on Monday. The company has a market capitalization of $49.86, a price-to-earnings ratio of 57.40 and a beta of -2.33. Opiant Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $51.90.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Monday, December 4th. The technology company reported ($2.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($1.58). The business had revenue of $0.02 million for the quarter. Opiant Pharmaceuticals had a net margin of 8.93% and a return on equity of 42.44%. research analysts anticipate that Opiant Pharmaceuticals will post -5.12 EPS for the current fiscal year.

In related news, major shareholder Geoffrey Wolf sold 2,570 shares of Opiant Pharmaceuticals stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $30.40, for a total transaction of $78,128.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 63.82% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Stock Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related stocks with our FREE daily email newsletter.